Loading

Osimertinib (Tagrisso®)

Dokument Fact Sheet
Spezifizierung Lungenkarzinom, nicht-kleinzellig (NSCLC) » EGFRmut » Stadium IB-IIIA
Stand Juli 2021
Dies ist die aktuell gültige Version des Dokuments

1Adjuvant Targeted Therapy, NSCLC EGFRmut, Stage IB-IIIA

1 N - number of patients5 OS - overall survival in months8 EFS - Event-Free Survival14 results for control, results for new therapy15 hazard ratio for new therapy18 n. r. – median not reached

Kommentare